Argenx says efgartigimod met main goal in myositis trial

argenx said its immunology drug efgartigimod met the primary endpoint in a late-stage study for adults with autoimmune myositis, delivering significant improvement in disease activity. The positive trial readout is a meaningful efficacy signal that should support the company’s clinical development and valuation outlook.

Analysis

argenx said its immunology drug efgartigimod met the primary endpoint in a late-stage study for adults with autoimmune myositis, delivering significant improvement in disease activity. The positive trial readout is a meaningful efficacy signal that should support the company’s clinical development and valuation outlook.